Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• LAG-3 and PD-L1 expression levels were analyzed based on the site of collection, revealing notable variations.
• High prevalence rates of LAG-3 and PD-L1 in patients could indicate tailored immunotherapy strategies.
• The analysis utilized biomarker assessments to enhance understanding of melanoma treatment response.
• Findings may support further investigations into the relationship between biomarker expression and therapy outcomes.